Keyword: Pfizer

Vyndaqel

10. Vyndaqel

Alnylam and Ionis may have been first and second to market with a drug for the rare disease transthyretin-mediated amyloidosis, but Pfizer’s Vyndaqel may yet carve itself a niche.